MedTrace Logo

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

NCT00514761 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2014-08-13

No results posted yet for this study

Summary

The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine. This study will also assess how safe and well tolerated AZD6244 is.

Conditions

Interventions

DRUG

AZD6244

oral vial

DRUG

Capecitabine

oral tablet

Sponsors & Collaborators

Principal Investigators

  • Clive Morris, MD · AstraZeneca

  • Gill Pover, MD · AstraZeneca

  • Lance Smith · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-06-30
Completion
2008-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514761 on ClinicalTrials.gov